The RAS oncogene hits the brake pedal on P53

Bart Westendorp

The RAS oncogene hits the brake pedal on P53

Pathobiology

Research output: Non-textual form › Web publication/site › Other research output

Abstract

We show that mutations in the RAS oncogene sensitizes cells to drugs that target replication stress. We found that overactive RAS blocked the gene transcription of P53. These findings suggest that cancer patients with intact P53 but mutant RAS may still benefit from ATR or CKH1 inhibitors.

Original language	English
Place of Publication	Cancer Community
Publisher	Nature Research
Media of output	Online
Publication status	Published - 8 Apr 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://cancercommunity.nature.com/posts/the-ras-oncogene-hits-the-brake-pedal-on-p53Licence: Unspecified

Cite this

@misc{88f865fabc30432083dadaa3fa17a828,

title = "The RAS oncogene hits the brake pedal on P53",

abstract = "We show that mutations in the RAS oncogene sensitizes cells to drugs that target replication stress. We found that overactive RAS blocked the gene transcription of P53. These findings suggest that cancer patients with intact P53 but mutant RAS may still benefit from ATR or CKH1 inhibitors. ",

author = "Bart Westendorp",

year = "2022",

month = apr,

day = "8",

language = "English",

publisher = "Nature Research",

}

TY - ADVS

T1 - The RAS oncogene hits the brake pedal on P53

AU - Westendorp, Bart

PY - 2022/4/8

Y1 - 2022/4/8

N2 - We show that mutations in the RAS oncogene sensitizes cells to drugs that target replication stress. We found that overactive RAS blocked the gene transcription of P53. These findings suggest that cancer patients with intact P53 but mutant RAS may still benefit from ATR or CKH1 inhibitors.

AB - We show that mutations in the RAS oncogene sensitizes cells to drugs that target replication stress. We found that overactive RAS blocked the gene transcription of P53. These findings suggest that cancer patients with intact P53 but mutant RAS may still benefit from ATR or CKH1 inhibitors.

M3 - Web publication/site

PB - Nature Research

CY - Cancer Community

ER -

The RAS oncogene hits the brake pedal on P53

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this